基于大型真实世界队列的癌症患者总生存增强预后评分
利用美国Flatiron Health电子健康记录数据库122 694例患者,在Cox比例风险框架下分析人口学、临床、常规血液学和血液生化参数,构建多变量预后风险模型ROPRO。ROPRO在非小细胞肺癌等瘤种中显示对总生存的预后价值,并在两项独立I期和III期临床研究中得到验证。
要点
- ROPRO由27个变量构成,跨瘤种独立且同质地贡献于总生存预后。
- 在晚期非小细胞肺癌中,ROPRO最高10%患者死亡风险为最低10%的7.91倍(95%CI 7.45-8.39)。
- ROPRO的C指数0.747(标准误0.001)和3个月AUC 0.822(0.819-0.825)优于Royal Marsden医院评分。
核心结论
- ROPRO提供了改进的总生存预后能力,在肿瘤临床开发中可用于患者分层、富集策略、数据解读和早期决策。
研究设计与样本
- 基于Flatiron Health电子健康记录去标识数据库,覆盖美国超过280个肿瘤中心,按瘤种分为17个队列。
- 在122 694例患者中,于Cox比例风险框架下分析人口学、临床、常规血液学和血液生化参数,构建多变量预后风险模型ROPRO。
- ROPRO在两项独立的I期和III期临床研究中进行了验证。
主要发现
- 共27个变量跨瘤种独立且同质地贡献于总生存。
- 在最大的晚期非小细胞肺癌队列中,ROPRO评分最高10%患者较最低10%患者的死亡风险增加7.91倍(95%CI 7.45-8.39)。
- ROPRO最低四分位Q1中位生存23.9个月(23.3-24.5),Q2为14.8个月(14.4-15.2),Q3为9.4个月(9.1-9.7),Q4为4.7个月(4.6-4.8)。
- ROPRO模型性能指标C指数=0.747(标准误0.001)、3个月AUC=0.822(0.819-0.825),优于Royal Marsden医院评分的C指数=0.54(标准误0.0005)、3个月AUC=0.579(0.577-0.581)。
- 在I期和III期临床试验中确认了ROPRO的高预后相关性。
临床怎么用
- ROPRO可用于肿瘤临床试验和真实世界数据中的患者分层与富集策略。
- ROPRO有助于临床研究的数据解读和早期决策。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: By understanding prognostic biomarkers, we gain insights into disease biology and may improve design, conduct, and data analysis of clinical trials and real-world data. In this context, we used the Flatiron Health Electronic Health Record-derived deidentified database that provides treatment outcome and biomarker data from >280 oncology centers in the USA, organized into 17 cohorts defined by cancer type. PATIENTS AND METHODS: In 122 694 patients, we analyzed demographic, clinical, routine hematology, and blood chemistry parameters within a Cox proportional hazard framework to derive a multivariable prognostic risk model for overall survival (OS), the 'Real wOrld PROgnostic score (ROPRO)'. We validated ROPRO in two independent phase I and III clinical studies. RESULTS: A total of 27 variables contributed independently and homogeneously across cancer indications to OS. In the largest cohort (advanced non-small-cell lung cancer), for example, patients with elevated ROPRO scores (upper 10%) had a 7.91-fold (95% confidence interval 7.45-8.39) increased death hazard compared with patients with low scores (lower 10%). Median survival was 23.9 months (23.3-24.5) in the lowest ROPRO quartile Q1, 14.8 months (14.4-15.2) in Q2, 9.4 months (9.1-9.7) in Q3, and 4.7 months (4.6-4.8) in Q4. The ROPRO model performance indicators [C-index = 0.747 (standard error 0.001), 3-month area under the curve (AUC) = 0.822 (0.819-0.825)] strongly outperformed those of the Royal Marsden Hospital Score [C-index = 0.54 (standard error 0.0005), 3-month AUC = 0.579 (0.577-0.581)]. We confirmed the high prognostic relevance of ROPRO in clinical Phase 1 and III trials. CONCLUSIONS: The ROPRO provides improved prognostic power for OS. In oncology clinical development, it has great potential for applications in patient stratification, patient enrichment strategies, data interpretation, and early decision-making in clinical studies.
引用
- Becker T, Weberpals J, Jegg AM, et al. An enhanced prognostic score for overall survival of patients with cancer derived from a large real-world cohort. Ann Oncol. 2020. PMID: 32739409. doi:10.1016/j.annonc.2020.07.013
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。